CA3078739A1 - Treating dementia with visual stimulation to synch gamma oscillations in brain - Google Patents
Treating dementia with visual stimulation to synch gamma oscillations in brainInfo
- Publication number
- CA3078739A1 CA3078739A1 CA3078739A CA3078739A CA3078739A1 CA 3078739 A1 CA3078739 A1 CA 3078739A1 CA 3078739 A CA3078739 A CA 3078739A CA 3078739 A CA3078739 A CA 3078739A CA 3078739 A1 CA3078739 A1 CA 3078739A1
- Authority
- CA
- Canada
- Prior art keywords
- subject
- visual stimuli
- mice
- chronic
- chronic visual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000007 visual effect Effects 0.000 title claims abstract description 202
- 210000004556 brain Anatomy 0.000 title claims abstract description 111
- 230000010355 oscillation Effects 0.000 title claims abstract description 41
- 206010012289 Dementia Diseases 0.000 title claims abstract description 20
- 230000000638 stimulation Effects 0.000 title description 136
- 230000001684 chronic effect Effects 0.000 claims abstract description 216
- 238000000034 method Methods 0.000 claims abstract description 142
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 137
- 210000000274 microglia Anatomy 0.000 claims abstract description 89
- 210000002442 prefrontal cortex Anatomy 0.000 claims abstract description 75
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 61
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 51
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 45
- 210000001320 hippocampus Anatomy 0.000 claims abstract description 41
- 230000001537 neural effect Effects 0.000 claims abstract description 37
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 32
- 230000010189 intracellular transport Effects 0.000 claims abstract description 22
- 230000028993 immune response Effects 0.000 claims abstract description 13
- 230000003977 synaptic function Effects 0.000 claims abstract description 12
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims abstract description 8
- 230000013016 learning Effects 0.000 claims abstract description 8
- 230000003959 neuroinflammation Effects 0.000 claims abstract description 8
- 230000008172 membrane trafficking Effects 0.000 claims abstract description 7
- 230000015654 memory Effects 0.000 claims abstract description 7
- 230000006951 hyperphosphorylation Effects 0.000 claims abstract description 5
- 210000002569 neuron Anatomy 0.000 claims description 68
- 230000002829 reductive effect Effects 0.000 claims description 68
- 210000000857 visual cortex Anatomy 0.000 claims description 61
- 210000004092 somatosensory cortex Anatomy 0.000 claims description 41
- 230000001965 increasing effect Effects 0.000 claims description 22
- 238000006366 phosphorylation reaction Methods 0.000 claims description 20
- 230000026731 phosphorylation Effects 0.000 claims description 19
- 230000001360 synchronised effect Effects 0.000 claims description 10
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 claims description 9
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 7
- 208000024806 Brain atrophy Diseases 0.000 claims description 6
- 230000017854 proteolysis Effects 0.000 claims description 6
- 230000005778 DNA damage Effects 0.000 claims description 5
- 231100000277 DNA damage Toxicity 0.000 claims description 5
- 210000000225 synapse Anatomy 0.000 claims description 5
- 108010036694 Dynamin I Proteins 0.000 claims description 4
- 102000000108 Dynamin-1 Human genes 0.000 claims description 4
- 108091006283 SLC17A7 Proteins 0.000 claims description 2
- 102000046052 Vesicular Glutamate Transport Protein 1 Human genes 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000000324 neuroprotective effect Effects 0.000 abstract description 13
- 230000006399 behavior Effects 0.000 abstract description 11
- 230000001404 mediated effect Effects 0.000 abstract description 9
- 230000004048 modification Effects 0.000 abstract description 8
- 238000012986 modification Methods 0.000 abstract description 8
- 238000013528 artificial neural network Methods 0.000 abstract description 3
- 230000028617 response to DNA damage stimulus Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 420
- 108010026424 tau Proteins Proteins 0.000 description 115
- 102000013498 tau Proteins Human genes 0.000 description 115
- 238000011818 5xFAD mouse Methods 0.000 description 78
- 235000018102 proteins Nutrition 0.000 description 49
- 230000014509 gene expression Effects 0.000 description 40
- 230000000694 effects Effects 0.000 description 38
- 102400000125 Cyclin-dependent kinase 5 activator 1, p25 Human genes 0.000 description 31
- 238000004458 analytical method Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 30
- 238000012347 Morris Water Maze Methods 0.000 description 24
- 210000004326 gyrus cinguli Anatomy 0.000 description 24
- 230000008569 process Effects 0.000 description 24
- 108090000765 processed proteins & peptides Proteins 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 238000010172 mouse model Methods 0.000 description 23
- 239000000523 sample Substances 0.000 description 22
- 238000007492 two-way ANOVA Methods 0.000 description 22
- 239000003550 marker Substances 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 238000012549 training Methods 0.000 description 19
- 230000007170 pathology Effects 0.000 description 18
- 230000009467 reduction Effects 0.000 description 16
- 230000003542 behavioural effect Effects 0.000 description 15
- 230000000946 synaptic effect Effects 0.000 description 15
- 230000005062 synaptic transmission Effects 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 238000003559 RNA-seq method Methods 0.000 description 14
- 230000001154 acute effect Effects 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 238000011002 quantification Methods 0.000 description 14
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 239000000872 buffer Substances 0.000 description 12
- 238000012937 correction Methods 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 108091005981 phosphorylated proteins Proteins 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 241000283074 Equus asinus Species 0.000 description 11
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 11
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 11
- 230000031018 biological processes and functions Effects 0.000 description 11
- 238000003364 immunohistochemistry Methods 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108010001441 Phosphopeptides Proteins 0.000 description 10
- 230000028973 vesicle-mediated transport Effects 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000000540 analysis of variance Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000001054 cortical effect Effects 0.000 description 9
- 238000012744 immunostaining Methods 0.000 description 9
- 230000001976 improved effect Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 101150013553 CD40 gene Proteins 0.000 description 8
- 210000005056 cell body Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000028709 inflammatory response Effects 0.000 description 8
- 238000011201 multiple comparisons test Methods 0.000 description 8
- 230000007470 synaptic degeneration Effects 0.000 description 8
- 239000012114 Alexa Fluor 647 Substances 0.000 description 7
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 7
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 7
- 230000001594 aberrant effect Effects 0.000 description 7
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000012110 Alexa Fluor 594 Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 6
- 230000003920 cognitive function Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000002025 microglial effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 206010010904 Convulsion Diseases 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 108010026552 Proteome Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 230000007792 alzheimer disease pathology Effects 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 208000010877 cognitive disease Diseases 0.000 description 5
- 230000005782 double-strand break Effects 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 230000000971 hippocampal effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 210000003140 lateral ventricle Anatomy 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 238000010606 normalization Methods 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 239000012103 Alexa Fluor 488 Substances 0.000 description 4
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 4
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 4
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000007625 higher-energy collisional dissociation Methods 0.000 description 4
- 238000010832 independent-sample T-test Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000006742 locomotor activity Effects 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 230000004112 neuroprotection Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000009877 rendering Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 102100026865 Cyclin-dependent kinase 5 activator 1 Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 3
- 238000012313 Kruskal-Wallis test Methods 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 238000000585 Mann–Whitney U test Methods 0.000 description 3
- 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 210000001130 astrocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000010468 interferon response Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 108010064131 neuronal Cdk5 activator (p25-p35) Proteins 0.000 description 3
- 238000012346 open field test Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000025915 regulation of apoptotic process Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003238 somatosensory effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 230000003363 transsynaptic effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
- -1 13-actin Proteins 0.000 description 2
- 208000027647 Cerebral Cortical Thinning Diseases 0.000 description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000891579 Homo sapiens Microtubule-associated protein tau Proteins 0.000 description 2
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 102100022033 Presenilin-1 Human genes 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000007623 carbamidomethylation reaction Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000032341 cell morphogenesis Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000006999 cognitive decline Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 230000021824 exploration behavior Effects 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000002546 full scan Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000001153 interneuron Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000022256 midbrain development Effects 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000008555 neuronal activation Effects 0.000 description 2
- 230000003955 neuronal function Effects 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003534 oscillatory effect Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 230000002360 prefrontal effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 210000002763 pyramidal cell Anatomy 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 230000004314 regulation of intracellular transport Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 2
- 238000012301 transgenic model Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000031836 visual learning Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 238000011825 3xTg-AD mouse Methods 0.000 description 1
- 101150053137 AIF1 gene Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 101000878595 Arabidopsis thaliana Squalene synthase 1 Proteins 0.000 description 1
- 206010009346 Clonus Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000012184 Diffuse Brain injury Diseases 0.000 description 1
- 102000043859 Dynamin Human genes 0.000 description 1
- 108700021058 Dynamin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108060005874 Parvalbumin Proteins 0.000 description 1
- 102000001675 Parvalbumin Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
- 239000004830 Super Glue Substances 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 101150044878 US18 gene Proteins 0.000 description 1
- 102000001763 Vesicular Glutamate Transport Proteins Human genes 0.000 description 1
- 108010040170 Vesicular Glutamate Transport Proteins Proteins 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007791 alzheimer disease like pathology Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007529 anxiety like behavior Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000023549 cell-cell signaling Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000007428 craniotomy Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 210000005110 dorsal hippocampus Anatomy 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000004070 electrodeposition Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000010201 enrichment analysis Methods 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 230000001787 epileptiform Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 102000057063 human MAPT Human genes 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- FXDLIMJMHVKXAR-UHFFFAOYSA-K iron(III) nitrilotriacetate Chemical compound [Fe+3].[O-]C(=O)CN(CC([O-])=O)CC([O-])=O FXDLIMJMHVKXAR-UHFFFAOYSA-K 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 230000008449 language Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 230000006740 morphological transformation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 229910001120 nichrome Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003068 pathway analysis Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 108091005626 post-translationally modified proteins Proteins 0.000 description 1
- 102000035123 post-translationally modified proteins Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000029588 regulation of mitotic cell cycle Effects 0.000 description 1
- 230000014786 regulation of synaptic transmission Effects 0.000 description 1
- 230000030796 regulation of vesicle-mediated transport Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000033504 synapse organization Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 208000028500 tonic seizure Diseases 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000032665 vasculature development Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0618—Psychological treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0022—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the tactile sense, e.g. vibrations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0027—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the hearing sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
- A61M2021/0044—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the sight sense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0626—Monitoring, verifying, controlling systems and methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/063—Radiation therapy using light comprising light transmitting means, e.g. optical fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
- A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0664—Details
- A61N2005/0667—Filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Psychology (AREA)
- Developmental Disabilities (AREA)
- Child & Adolescent Psychology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Social Psychology (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Radiation-Therapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570250P | 2017-10-10 | 2017-10-10 | |
| US62/570,250 | 2017-10-10 | ||
| US201762570929P | 2017-10-11 | 2017-10-11 | |
| US62/570,929 | 2017-10-11 | ||
| USPCT/US2018/051785 | 2018-09-19 | ||
| PCT/US2018/055258 WO2019075094A1 (en) | 2017-10-10 | 2018-10-10 | TREATMENT OF DEMENTIA BY VISUAL STIMULATION TO INDUCE SYNCHRONIZED GAMA OSCILLATIONS IN THE BRAIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3078739A1 true CA3078739A1 (en) | 2019-04-18 |
Family
ID=83459525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3078739A Pending CA3078739A1 (en) | 2017-10-10 | 2018-10-10 | Treating dementia with visual stimulation to synch gamma oscillations in brain |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3694593A4 (ko) |
| JP (1) | JP2020536643A (ko) |
| KR (2) | KR20200086277A (ko) |
| CN (1) | CN111655319A (ko) |
| AU (2) | AU2018347366B2 (ko) |
| CA (1) | CA3078739A1 (ko) |
| WO (1) | WO2019075094A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230095907A1 (en) | 2019-10-18 | 2023-03-30 | Institute Of Science And Technology Austria | Stimulation of neuronal plasticity |
| KR20210053631A (ko) * | 2019-11-04 | 2021-05-12 | 한국과학기술원 | 가시광선을 이용하여 감마 대역의 뇌파를 활성화하는 방법 및 이를 위한 시각 자극 제공 장치 |
| KR102400319B1 (ko) * | 2021-12-31 | 2022-05-24 | (주)리솔 | 객체의 복수의 뇌 영역에서 동기화된 진동을 동조시킴으로써, 뇌를 자극하는 장치 및 방법 |
| CN116407766A (zh) | 2021-12-31 | 2023-07-11 | 株式会社利率 | 定制型经颅交流电刺激装置及方法 |
| KR102425066B1 (ko) * | 2022-03-25 | 2022-07-28 | (주)리솔 | 실시간 eeg 신호 모니터링을 기초로, 뇌에서 동기화된 뇌파진동을 동조시키는 맞춤형 경두개교류전기자극 장치 및 방법 |
| KR102577515B1 (ko) | 2022-11-21 | 2023-09-12 | 이종설 | 파동자극 생성기기 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2136654T3 (es) * | 1991-12-06 | 1999-12-01 | Max Planck Gesellschaft | Herramientas para el diagnostico y tratamiento de la enfermedad de alzheimer. |
| JP3648802B2 (ja) * | 1994-09-27 | 2005-05-18 | 松下電工株式会社 | 光治療用高照度光照射装置 |
| EP1814630A4 (en) * | 2004-11-15 | 2008-05-07 | Christopher Decharms | APPLICATIONS FOR NERVE BEND STIMULATION BY LIGHT |
| US20080181882A1 (en) * | 2006-11-15 | 2008-07-31 | The University Of Pennsylvania | Neurgulin 1 (NRG1) - ErbB4 signaling as a target for the treatment of schizophrenia |
| WO2008147958A1 (en) * | 2007-05-25 | 2008-12-04 | Thomas Jefferson University | Method of treatment to improve concentration and/or memory in a subject in need thereof |
| DE102008012669B8 (de) * | 2008-03-05 | 2011-03-03 | Anm Adaptive Neuromodulation Gmbh | Vorrichtung und Verfahren zur visuellen Stimulation |
| ITRM20090027A1 (it) * | 2009-01-26 | 2010-07-27 | Alain Rocco | Apparato di stimolazione per il trattamento del dolore e relativo metodo di funzionamento. |
| WO2012024243A1 (en) * | 2010-08-16 | 2012-02-23 | Photothera, Inc. | Minimally invasive low level light therapy for neurological disorders |
| WO2013061597A1 (ja) * | 2011-10-25 | 2013-05-02 | 学校法人金沢医科大学 | 認知症状やうつ様症状改善のための光照射装置、この光照射装置を備えた部屋、及び認知症状やうつ様症状改善のための照明器具 |
| US9272118B1 (en) * | 2012-03-02 | 2016-03-01 | George Acton | Methods for treating brain malfunctions |
| US20150337030A1 (en) * | 2012-05-31 | 2015-11-26 | The Trustees Of Columbia University In The City Of New York | Methods to treat alzheimer's disease using apoe inhibitors |
| US20140303025A1 (en) * | 2013-03-15 | 2014-10-09 | The Translational Genomics Research Institute | Methods for the diagnosis and prognosis of neurodegenerative diseases |
| EP3065818B1 (en) * | 2013-11-04 | 2020-05-27 | Phoenix NeuroStim Therapeutics, LLC | Device for the treatment of central nervous system conditions using sensory stimulus |
| WO2015149170A1 (en) * | 2014-03-31 | 2015-10-08 | Functional Neuromodulation, Inc. | Systems and methods for determining a trajectory for a brain stimulation lead |
| EP3180080B1 (en) * | 2014-08-14 | 2021-01-06 | Functional Neuromodulation, Inc. | Brain stimulation system including multiple stimulation modes |
| KR102603963B1 (ko) * | 2015-11-24 | 2023-11-20 | 메사추세츠 인스티튜트 오브 테크놀로지 | 치매를 예방, 경감 및/또는 치료하기 위한 시스템 및 방법 |
| WO2017172728A1 (en) * | 2016-03-28 | 2017-10-05 | Duke University | Systems and methods for brain stimulation |
-
2018
- 2018-10-10 KR KR1020207013291A patent/KR20200086277A/ko not_active Application Discontinuation
- 2018-10-10 CN CN201880077874.3A patent/CN111655319A/zh active Pending
- 2018-10-10 WO PCT/US2018/055258 patent/WO2019075094A1/en unknown
- 2018-10-10 JP JP2020520207A patent/JP2020536643A/ja active Pending
- 2018-10-10 EP EP18866752.1A patent/EP3694593A4/en active Pending
- 2018-10-10 CA CA3078739A patent/CA3078739A1/en active Pending
- 2018-10-10 KR KR1020237001501A patent/KR20230015501A/ko not_active Application Discontinuation
- 2018-10-10 AU AU2018347366A patent/AU2018347366B2/en active Active
-
2022
- 2022-11-15 AU AU2022271389A patent/AU2022271389A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020536643A (ja) | 2020-12-17 |
| EP3694593A1 (en) | 2020-08-19 |
| KR20230015501A (ko) | 2023-01-31 |
| KR20200086277A (ko) | 2020-07-16 |
| AU2022271389A1 (en) | 2022-12-15 |
| AU2018347366B2 (en) | 2022-09-15 |
| AU2018347366A1 (en) | 2020-04-23 |
| WO2019075094A1 (en) | 2019-04-18 |
| EP3694593A4 (en) | 2021-07-21 |
| CN111655319A (zh) | 2020-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10960225B2 (en) | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function | |
| AU2018347366B2 (en) | Treating dementia with visual stimulation to synch gamma oscillations in brain | |
| Adaikkan et al. | Gamma entrainment binds higher-order brain regions and offers neuroprotection | |
| Badimon et al. | Negative feedback control of neuronal activity by microglia | |
| Koranda et al. | Mettl14 is essential for epitranscriptomic regulation of striatal function and learning | |
| Ballinger et al. | Basal forebrain cholinergic circuits and signaling in cognition and cognitive decline | |
| Winkelmann et al. | Changes in neural network homeostasis trigger neuropsychiatric symptoms | |
| Faivre et al. | Neuroprotective effects of D-Ala 2 GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model | |
| Zhao et al. | Specific depletion of the motor protein KIF5B leads to deficits in dendritic transport, synaptic plasticity and memory | |
| CA2984645C (en) | Methods and compositions for treating aging-associated impairments | |
| Vasconcelos et al. | Social defeat protocol and relevant biomarkers, implications for stress response physiology, drug abuse, mood disorders and individual stress vulnerability: a systematic review of the last decade | |
| Sherpa et al. | Retinal regeneration is facilitated by the presence of surviving neurons | |
| Slattery et al. | Selective breeding for high anxiety introduces a synonymous SNP that increases neuropeptide S receptor activity | |
| Bowling et al. | Shaping dendritic spines in autism spectrum disorder: mTORC1-dependent macroautophagy | |
| Zapata et al. | Epilepsy and intellectual disability linked protein Shrm4 interaction with GABABRs shapes inhibitory neurotransmission | |
| Zhang et al. | TMEM25 modulates neuronal excitability and NMDA receptor subunit NR2B degradation | |
| Morandell et al. | Cul3 regulates cytoskeleton protein homeostasis and cell migration during a critical window of brain development | |
| Eltokhi et al. | Imbalanced post-and extrasynaptic SHANK2A functions during development affect social behavior in SHANK2-mediated neuropsychiatric disorders | |
| Bhatti et al. | Molecular and cellular adaptations in hippocampal parvalbumin neurons mediate behavioral responses to chronic social stress | |
| Demuth et al. | Deletion of p75NTR rescues the synaptic but not the inflammatory status in the brain of a mouse model for Alzheimer’s disease | |
| WO2020227213A1 (en) | Methods of controlling and improving brain health | |
| Sultan et al. | Gadd45 in neuronal development, function, and injury | |
| Hanzel et al. | Mice lacking Astn2 have ASD-like behaviors and altered cerebellar circuit properties | |
| Tapnikar | Neurogenic Plasticity in a Serotonin Transporter Knockout Model: Effects of Maternal and Offspring Genotype | |
| Forston | Novel insights into oligodendrocyte biology from developmental myelination studies in autophagy deficient mice and analysis of oligodendrocyte translatome response to contusive spinal cord injury. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231010 |
|
| EEER | Examination request |
Effective date: 20231010 |
|
| EEER | Examination request |
Effective date: 20231010 |
|
| EEER | Examination request |
Effective date: 20231010 |
|
| EEER | Examination request |
Effective date: 20231010 |